HAYWARD, Calif., April 13 /PRNewswire/ -- Metabolex, Inc., a biopharmaceutical company focused on the discovery and development of proprietary new medicines for the treatment of metabolic diseases, announced today the initiation of a research collaboration with Takeda San Francisco, Inc. (TSF), a wholly owned subsidiary of Takeda Pharmaceutical Company Limited.
Harold Van Wart, Ph.D., President and Chief Executive Officer of Metabolex said "We are very excited about this partnership with TSF, Takeda's center of excellence for antibody research. The collaboration brings together Metabolex's expertise in diabetes and metabolic disease targets with TSF's deep strength in antibody drug discovery and non-clinical development."
Metabolex is a privately-held biopharmaceutical company focused on the discovery and development of proprietary new medicines for the treatment of metabolic diseases, with an emphasis on type 2 diabetes. The company has four clinical-stage compounds: MBX-102, which has completed three Phase 2 trials; MBX-2044, which has completed a Phase 2a trial; MBX-8025, which has completed a Phase 2 trial in patients with dyslipidemia; and MBX-2982, which recently completed its third Phase 1 trial.